Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthesis method of antiviral nucleoside analogue

A technology of compounds and structural formulas, applied in the field of nucleoside analog synthesis, can solve the problems of difficult separation and purification of ring-opening reaction products, difficult to complete, complicated processes, etc.

Active Publication Date: 2008-02-27
CHIA TAI TIANQING PHARMA GRP CO LTD +1
View PDF6 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] 1. The yield of the ring-opening reaction is low: for example, the yield reported in WO9809964 is about 50%, and the yield reported in JOC1985, 50, 755 is 27%
[0006] 2. It is difficult to separate and purify the ring-opening reaction product, which requires multiple column chromatography. The ring-opening reaction product is a mixture of stereoisomers. Even after repeated purification by silica gel column chromatography, it is still difficult to separate from each other and affects the final product purity
[0007] 3. The amino group on guanine needs to be protected in the follow-up reaction, the protection reaction is difficult, the product is unstable, the separation is complicated, and column chromatography is required. For example, WO9809964 reports that the reaction of protecting the amino group on guanine with MMT is difficult to complete, and the product is difficult to complete in the subsequent reaction. The purification process requires silica gel column chromatography, and it is easy to decompose on the silica gel column
[0009] Therefore, the reaction route of directly using guanine ring-opening is not suitable for industrial production in the process of actual use with complicated process, high yield and low cost.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis method of antiviral nucleoside analogue
  • Synthesis method of antiviral nucleoside analogue
  • Synthesis method of antiviral nucleoside analogue

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1: [1s-(1α, 2β, 3α, 5β)]-5-(phthalimide)-3-(benzyloxy)-2-[(benzyloxy)methyl base] cyclopentanol (intermediate 2') preparation

[0065] In a 5L three-neck flask, add 145g (0.98mol) of phthalimide, 3.77g of LiH and 765ml of anhydrous DMF, and stir for 10min. After heating to 60°C, stir for 15 minutes, at which time the cloudy solution becomes clear. Slowly drop 152g (0.49mol) [1s-(1α, 2α, 3β, 5α)]-3-(benzyloxy)-2-[(benzyloxy)methyl] dissolved in 1.87L of anhydrous DMF -6-Oxabicyclo[3.1.0]hexane (intermediate 1'), stirred at 60°C for 15min. Heated to 125°C, reacted for 2 hours, TLC (B: positive = 1:3) showed that the raw material disappeared, and terminated the reaction with 28ml of glacial acetic acid. Stir for 10 min. Add 2.5 L of saturated brine, extract with 3×1.2 L of ethyl acetate, combine the organic phases, wash once with saturated brine, dry over anhydrous sodium sulfate, and recover the solvent. The remaining oil was separated on a silica gel column ...

Embodiment 2

[0069] Example 2: [1s-(1α, 2β, 3α, 5β)]-5-[phthalimide]-3-(benzyloxy)-2-[(benzyloxy)methyl Base] the preparation of cyclopentanone (intermediate 3')

[0070] In a 3L three-necked flask, add 203g of Dess-Martin reagent, add 1.4L of anhydrous CH 2 Cl 2 Stir. 137.7g intermediate 2' was dissolved in 890ml anhydrous CH 2 Cl 2 Dissolved and added dropwise to the suspension in the previous step. After 20 min, TLC (B:positive=1:3) showed that the raw material disappeared, and the reaction was stopped. NaHSO 3 Washed three times with saturated aqueous solution, and then washed with NaHCO 3 Washed with saturated aqueous solution for 3 times, and finally washed with saturated brine for 3 times, and the organic layer was dehydrated and dried to obtain 196 g of a yellow oily compound.

Embodiment 3

[0071] Example 3: 1s-(1α, 3α, 4β)-5-phthalimido-2-methylene-4-(benzyloxy)-3-[(benzyloxy)methanol Preparation of Cyclopentane (Intermediate 4')

[0072] In a 5L three-necked flask, add Nysted Reagent (Wt=20%) 1.46L and 800ml anhydrous THF, stir, N 2 Protected and cooled to -78°C. 196g intermediate 3' with appropriate amount of CH 2 Cl 2 Dissolved and added dropwise to the reaction. Take TiCl 4 / CH 2 Cl 2 (1:9) 393ml was slowly added dropwise to the reaction, maintaining the temperature at -60°C to 78°C. After the dropwise addition was completed, the mixture was maintained at -78°C for 15 min. Slowly warm up to room temperature, and continue to stir for 1-3 h. TLC (B: positive = 1:4) showed that the raw materials disappeared, and the reaction solution was purple-black. Pour this reaction solution into 2.3L saturated NaHCO 3 In the middle, stir thoroughly, and white turbidity will appear at this time. Extracted three times with ethyl acetate, back-extracted once with s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a synthesizing method of entikawei with antiviral activity, which relates to the intermediate to prepare entikawei and making method of the intermediate.

Description

technical field [0001] The present invention relates to a synthesis method of nucleoside analogues, in particular to a synthesis method of entecavir, a compound with antiviral activity, and also relates to intermediates for preparing entecavir and methods for preparing these intermediates. Background technique [0002] Entecavir (entecavir) is a carbocyclic guanosine analogue, chemical name: [1S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3 -Hydroxymethyl-2-methylenecyclopentyl]-6H-purolin-6-one; Molecular formula: C 12 h 15 o 3 N 5 , molecular weight 277.3; the chemical structural formula is as follows: [0003] [0004] Entecavir is an effective anti-hepatitis B virus therapeutic drug. The compound and its monohydrate and sodium salt can be used for the treatment of hepatitis B. The report on entecavir and its use as an antiviral drug first appeared in the U.S. Patent US5206244; CN1310999 and CN1658844 describe entecavir low-dose pharmaceutical composition for t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D473/18C07D239/48C07D239/50
CPCY02P20/55
Inventor 袁建栋张喜全刘飞张凯叶新建葛雅
Owner CHIA TAI TIANQING PHARMA GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com